Completed PHASE3 INTERVENTIONAL 5-arm NCT01365455

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Sponsor: Novartis Pharmaceuticals

Conditions Moderate to Severe Plaque-type Psoriasis

Interventions placebo to secukinumab 150 mg secukinumab 150 mg

Updated 9 times since 2017 Last updated: Dec 9, 2020 Started: Jun 30, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01365455, this PHASE3 trial focuses on Moderate to Severe Plaque-type Psoriasis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Feb 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

May 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — May 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Ann Arbor, United States , Asahikawa, Japan , Austin, United States , Barranquilla, Colombia , Birmingham, United States , Boca Raton, United States , Bogotá, Colombia , Bryan, United States , Bucaramanga, Colombia and 64 more locations